IL147643A0 - Drug therapy of the restless leg syndrome - Google Patents

Drug therapy of the restless leg syndrome

Info

Publication number
IL147643A0
IL147643A0 IL14764300A IL14764300A IL147643A0 IL 147643 A0 IL147643 A0 IL 147643A0 IL 14764300 A IL14764300 A IL 14764300A IL 14764300 A IL14764300 A IL 14764300A IL 147643 A0 IL147643 A0 IL 147643A0
Authority
IL
Israel
Prior art keywords
drug therapy
restless leg
leg syndrome
syndrome
restless
Prior art date
Application number
IL14764300A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of IL147643A0 publication Critical patent/IL147643A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL14764300A 1999-08-19 2000-08-09 Drug therapy of the restless leg syndrome IL147643A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19938823A DE19938823A1 (de) 1999-08-19 1999-08-19 Medikamentöse Behandlung des Restless Leg Syndroms
PCT/EP2000/007719 WO2001013903A2 (de) 1999-08-19 2000-08-09 Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid

Publications (1)

Publication Number Publication Date
IL147643A0 true IL147643A0 (en) 2002-08-14

Family

ID=7918572

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14764300A IL147643A0 (en) 1999-08-19 2000-08-09 Drug therapy of the restless leg syndrome

Country Status (21)

Country Link
US (1) US20010053777A1 (de)
EP (1) EP1210076A2 (de)
JP (1) JP2003513014A (de)
KR (1) KR20020020273A (de)
CN (1) CN1368878A (de)
AR (1) AR025329A1 (de)
AU (1) AU6836500A (de)
BR (1) BR0013355A (de)
CA (1) CA2382648A1 (de)
CO (1) CO5190708A1 (de)
CZ (1) CZ2002516A3 (de)
DE (1) DE19938823A1 (de)
IL (1) IL147643A0 (de)
MX (1) MXPA02001295A (de)
NO (1) NO20020792D0 (de)
PE (1) PE20010738A1 (de)
PL (1) PL364871A1 (de)
SK (1) SK2452002A3 (de)
TR (1) TR200200450T2 (de)
UY (1) UY26296A1 (de)
WO (1) WO2001013903A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
BR0110188A (pt) * 2000-04-21 2003-03-05 Upjohn Co Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica
CA2405565A1 (en) 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
JP4453254B2 (ja) * 2001-03-30 2010-04-21 東レ株式会社 レストレス・レッグズ症候群治療薬
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
EP1387673B1 (de) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Opioid enthaltende arzneiform gegen missbrauch
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
LT2425821T (lt) 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
AU2003257418A1 (en) * 2002-06-19 2004-01-06 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DK1426049T3 (da) 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
EP1604667A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung des Restless Leg Syndroms
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
KR100905511B1 (ko) * 2005-01-28 2009-07-01 유로-셀띠끄 소시에떼 아노님 알코올 저항성 제형
EP1695700A1 (de) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Darreichungsform enthaltend Oxycodon und Naloxon
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
EP1813276A1 (de) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Manipulationssichere Dosierformen
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
WO2008079727A2 (en) * 2006-12-22 2008-07-03 Allergan, Inc. Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
EP2363116A1 (de) * 2008-06-25 2011-09-07 US Worldmeds LLC Lofexidin enthaltende Formulierungen mit verzögerter Freisetzung zur oralen Verabreichung
PL2405915T3 (pl) 2009-03-10 2019-05-31 Euro Celtique Sa Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
EP2858649B1 (de) * 2012-06-11 2019-10-23 Psychogenics Inc. Behandlung von nebenwirkungen motorischer und bewegungsstörung im zusammenhang mit morbus-parkinson-behandlungen
KR20160034352A (ko) 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
KR101891185B1 (ko) 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
TWI709417B (zh) 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
CN110446533A (zh) * 2016-09-13 2019-11-12 思想实验室有限责任公司 不宁腿综合征的药品组合与治疗
KR20190060007A (ko) 2016-10-31 2019-05-31 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치를 이용한 통증을 관리하는 방법
EP3906927B1 (de) * 2020-05-04 2022-05-25 BIOPROJET Pharma Verwendung von dopamin-d3-teilagonisten zur behandlung von störungen des zentralen nervensystems
JP2025509432A (ja) * 2022-03-09 2025-04-11 マインドステイト デザイン ラボズ、インコーポレイテッド エンタクトゲン心理状態を設計および生成するための治療的組み合わせ、組成物、および方法
CN115154448B (zh) * 2022-08-04 2024-01-30 谭竞 一种治疗不宁腿综合征的药物及其制备方法和应用
WO2025255416A1 (en) * 2024-06-05 2025-12-11 TMTRx, Inc. Fentanyl and fentanyl analogue overdose reversal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
DE19749724A1 (de) * 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
TR200200450T2 (tr) 2002-08-21
NO20020792L (no) 2002-02-18
CA2382648A1 (en) 2001-03-01
KR20020020273A (ko) 2002-03-14
AU6836500A (en) 2001-03-19
AR025329A1 (es) 2002-11-20
US20010053777A1 (en) 2001-12-20
UY26296A1 (es) 2001-04-30
PE20010738A1 (es) 2001-07-16
WO2001013903A2 (de) 2001-03-01
CO5190708A1 (es) 2002-08-29
DE19938823A1 (de) 2001-02-22
CZ2002516A3 (cs) 2002-05-15
EP1210076A2 (de) 2002-06-05
CN1368878A (zh) 2002-09-11
MXPA02001295A (es) 2002-08-12
WO2001013903A3 (de) 2001-08-23
SK2452002A3 (en) 2002-06-04
PL364871A1 (en) 2004-12-27
NO20020792D0 (no) 2002-02-18
BR0013355A (pt) 2002-04-30
JP2003513014A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
IL149224A0 (en) Hydrogen-driven drug dosage form
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL148496A0 (en) Therapeutic quinazoline derivatives
GB9929407D0 (en) Patient support
PL364871A1 (en) Treatment of restless leg syndrome with a combination of clonidine and opioid
AU7882900A (en) Hydrotherapy bed
AU7270700A (en) Sock or stocking for therapeutic use
ZA200110436B (en) Therapeutic use of melatonin.
HUP0001913A3 (en) Use of pramipexole for the preparation of pharmaceutical compositions treating restless legs syndrome
AU3922900A (en) Use of (valeriana) for the treatment of restless leg syndrome and related disorders
DE60015634D1 (de) Krankenliege
DE69936634D1 (de) Medizinischer Kompressionsartikel
GB9911238D0 (en) Therapeutic use
GB9930563D0 (en) Absorbent medicinal articles
IL149653A0 (en) 2-arylquinoline derivatives, preparation and therapeutic use thereof
TW382948U (en) Improved structure for the leg locking structure of chairs
GB9928691D0 (en) Article of furniture
GB9924593D0 (en) Patient support tables
PL109749U1 (en) Piece of furniture
TW379549U (en) Structure of chair leg
TW391252U (en) Massaging bed
TW398224U (en) Improved structure of the adjustable legs of furniture
TW389067U (en) Chair leg structure
GB0024093D0 (en) Treatment of the insulin resistance syndrome
GB0030649D0 (en) Treatment of the insulin resistance syndrome